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ABSTRACT: A tapered optical ﬁber (TOF) plasmonic biosensor was
fabricated and used for the sensitive detection of a panel of microRNAs
(miRNAs) in human serum obtained from noncancer and prostate
cancer (PCa) patients. Oncogenic and tumor suppressor miRNAs let7a, let-7c, miR-200b, miR-141, and miR-21 were tested as predictive
cancer biomarkers since multianalyte detection minimizes false-positive
and false-negative rates and establishes a strong foundation for early
PCa diagnosis. The biosensing platform integrates metallic gold
triangular nanoprisms (AuTNPs) laminated on the TOF to excite
surface plasmon waves in the supporting metallic layer and enhance the
evanescent mode of the ﬁber surface. This sensitive TOF plasmonic
biosensor as a point-of-care (POC) cancer diagnostic tool enabled the
Spectrometer
detection of the panel of miRNAs in seven patient serums without any
RNA extraction or sample ampliﬁcation. The TOF plasmonic biosensor could detect miRNAs in human serum with a limit of
detection between 179 and 580 aM and excellent selectivity. Statistical studies were obtained to diﬀerentiate cancerous from
noncancerous samples with a p-value <0.0001. This high-throughput TOF plasmonic biosensor has the potential to expand and
advance POC diagnostics for the early diagnosis of cancer.

1. INTRODUCTION
Cancer is the second leading cause of death globally, and it
costs our nation too many lives and consumes resources. In
2018, 9.6 million people died from this disease.1 Among all of
the cancers, breast cancer and prostate cancer (PCa) are the
two most diagnosed cancers in women and men, respectively.
PCa is the second most frequent malignancy in men with over
1.3 million new cases and 358 989 deaths worldwide, thereby
representing 3.8% of all deaths caused by cancer in men in
2018.2 The majority of PCa is adenocarcinoma, which appears
in the secretory epithelial cells of prostatic ducts.3 Currently, a
symptom-based approach is used to diagnose PCa followed by
an identiﬁcation blood test to detect the prostate-speciﬁc
antigen (PSA) concentration level in the serum. When the PSA
level exceeds the threshold concentration of 4 ng/mL, further
investigation is necessitated via a digital rectal examination and
tissue biopsy. These approaches are invasive, increase
discomfort levels for patients, and can carry procedural
risks.4 However, the biggest burden associated with PSA
screening is that two-thirds of positive PSA tests are in fact
false positives due to the low speciﬁcity of the PSA biomarker
for PCa and one-ﬁfth of PSA testing results in false negatives,
missing men with signiﬁcant PCa disease. Although biomarkerbased diagnostics continue to play an important role in the
detection of cancer, biomarkers with high speciﬁcity to PCa
have not been explored. Therefore, there is an unmet need for

V

ACS Publications

© 2022 The Authors. Published by
American Chemical Society

a noninvasive PCa test that can distinguish healthy vs.
cancerous cells more speciﬁcally than PSA.
Early diagnosis using biomarkers speciﬁc to PCa can greatly
enhance the PCa survival rate and minimize the cost associated
with the overall treatment.5,6 MicroRNAs (MiRNAs) as
biomarkers have garnered signiﬁcant attention because of the
critical role they play in various physiological and pathological
progresses, including carcinogenesis.7−13 MiRNAs are small
noncoding RNAs of ∼19 to 22 nucleotides in length, which are
capable of modulating gene activity at the post-transcriptional
level. MiRNAs are commonly dysregulated in tissues and ﬂuids
(i.e., serum) of cancer patients compared to normal
populations, and these expression proﬁles closely correlate
with disease aggressiveness, disease prognosis, and therapy
response.14 Functional studies indicate that aberrant miRNA
expression directly impacts prostate tumorigenesis by targeting
factors that control cell cycle progression, apoptosis, DNA
repair, diﬀerentiation, androgen signaling, angiogenesis,
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---Scheme 1. (A) Schematic Representation of the Fabricated Tapered Optical Fiber (TOF) Biosensing Platform. (B) Gold
Triangular Nanoprisms (AuTNPs) Covalently Bonded to the TOF. (C) Immobilized Single-Stranded DNA (ssDNA) and
Poly(ethylene Glycol)-Thiol (PEG-SH) as Bioreceptor and Spacer, Respectively. (D) Hybridization of Target miRNA to
ssDNA in a Complex Serum Environment that Contains Other Endogenous Biomolecules
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biomarkers in serum and its potential application in point-ofcare testing.
In our previous work, we reported on the successful
fabrication of a tapered optical ﬁber (TOF) plasmonic
biosensors for detection of a panel of prostate tumor
suppressor and oncogenic miRNAs (let-7a, let-7c, miR-141,
miR-21, miR-200b) diluted in standard buﬀered solution.
Since TOFs are very sensitive to changes in the surrounding
refractive index and the input light wavelength, we employed
highly sensitive metallic nanostructure laminated on the TOF
region to enhance the evanescent ﬁeld to make the biosensor
more sensitive to the local surface plasmon waves.25 Herein,
we report the improved use of TOF plasmonic biosensors to
achieve highly sensitive and speciﬁc detection of miRNAs in
PCa patient biological ﬂuids (serum) while mitigating
nonspeciﬁc binding for surface-based biosensors. Poly(ethylene glycol)-thiol (PEG-SH) was used as a spacer
molecule to minimize nonspeciﬁc adsorption of endogenous
biomolecules and provided excellent antifouling eﬀects. The
use of the TOF plasmonic biosensor enabled the sensitive
detection of a panel of miRNAs in seven patient serums
representing noncancer, low-risk, and high-risk PCa, and
expression proﬁling did not require RNA extraction or sample
ampliﬁcation. Expression proﬁles for let-7a and let-7c obtained
by qRT-PCR correlated with the biosensor data. This work
implicates the possibility of using TOF plasmonic biosensors
for rapid and noninvasive diagnostic screening and early PCa
detection using multianalyte detection of miRNAs biomarkers
to minimize false-positive and false-negative rates and establish
a strong foundation for early PCa diagnosis.

hypoxia, and chromatin remodeling. Oncogenic miRNAs are
commonly overexpressed in PCa patients and promote cancer
development by blocking tumor suppressor genes (i.e., TP53,
PTEN). Similarly, prostate tumor suppressor miRNAs are
underexpressed in cancer patients and act to inhibit malignant
growth by targeting oncogenic factors and regulate cancer cell
diﬀerentiation or apoptosis.15,16 Mass-spectrometry imaging
has gained signiﬁcant attention for the development of labelfree chemical imaging approaches in biological samples.17−19
Laser desorption/ionization mass-spectrometry (LDI-MS)based metabolic ﬁngerprinting was recently explored for the
diagnosis medulloblastoma, wherein the machine learning
algorithm implemented correctly diﬀerentiated medulloblastoma patients from healthy controls using a panel of serum
metabolite biomarkers.18 Pei et al. demonstrated LDI-MSbased metabolic ﬁngerprinting in successfully diagnosing
gynecological cancers.19 However, these techniques require
sophisticated instrumentation and sample pretreatment prior
to imaging and thus further limit point-of-care testing.
Diﬀerent from LDI-MS, optical biosensors have been
demonstrated to simplify the assay and enable the direct
detection of nucleic acids.20,21 Quantitative measurement of
miRNAs has been achieved with microarrays and quantitative
real-time polymerase chain reaction (qRT-PCR) technologies;
however, these techniques are expensive and labor-intensive,
requiring sample preparation and ampliﬁcation steps.22
Consequently, surface-enhanced Raman scattering (SERS)
continues to garner signiﬁcant attention as a powerful tool for
measuring metabolites in biological ﬂuids.23,24 To enhance the
performance of surface-enhanced Raman scattering (SERS)based immunoassay, a linear support vector machine algorithm
was demonstrated to successfully classify PCa, benign prostate
hyperplasia (BPH), and healthy subjects using SERS-based
immunoassay with an accuracy rate of 50% using serum PSA,
and the classiﬁcation performance increased to 70% when
multiple tumor markers were used,23 thereby illustrating the
eﬀectiveness of machine learning in analyzing multiple tumor

2. MATERIALS AND METHODS
2.1. Materials. Chloro(triethyl phosphine) gold (I)
(Et3PAuCl, 97%), poly(methylhydrosiloxane) (PMHS, Mn =
1700−3300), and triethylamine (TEA, 98%) were procured
from Sigma-Aldrich. ACS grade acetonitrile (CH3CN, 99.9%),
ethanol (22 proof), and (3-mercaptopropyl)-trimethoxysilane
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poly(ethylene glycol)-thiol (PEG-SH (1:1000)) solution was
added and allowed to react overnight, followed by rinsing in
PBS to remove any unbound reactants. The resulting ssDNA/
PEG-functionalized TOF serves as the TOF plasmonic
biosensor ready for the detection of target miRNA molecules
from human serum samples.
2.6. Human Serum Samples. The deidentiﬁed human
serum samples were obtained from the Eastern Virginia
Medical School (EVMS) Biorepository under protocols was
approved by the EVMS Institutional Review Board and in
accordance with NIH guidelines and HIPAA regulations.
Serum was grouped based on pathological grade: noncancer
(three patients), low-risk cancer group (pT2a, Gleason 6, ISUP
Grade Group 1; two patients), and high-risk cancer group
(pT3, Gleason 8 or Gleason 9, ISUP Grade Group 4/5; two
patients). A quality control (QC) human serum specimen
representing a pool of 360 noncancer individuals was used as a
control. Whole blood samples were initially collected in a
serum vacutainer tube, centrifuged at 3000g for 15 min, and
the collected serum was aliquoted and stored at −80 °C until
proﬁled for miRNA expression. The 40% human serum was
prepared by diluting 400 μL of QC serum in 600 μL of 1×
PBS.
2.7. Serum Total RNA Isolation and qRT-PCR
Detection of miRNAs. Total RNA was isolated from 350
mL of human serum (NC, LR, HR, QC) using a modiﬁed
protocol for the miRNeasy Mini Kit (Qiagen). Speciﬁcally, 700
μL of QIAZol Lysis Reagent was added to the serum sample
and incubated for 5 min at room temperature. Then, 140 μL of
chloroform was added and mixed brieﬂy and centrifuged for 15
min at 12 100 RPM at 4 °C. The upper aqueous layer was
extracted and 1.5 volumes (1200 μL) of 100% ethanol was
added and mixed. The sample was then loaded onto the
miRNeasy mini column and the remaining protocol was
followed. Total RNA was eluted with 50 μL of nuclease-free
water, and 9.16 μL of eluted total RNA was used for each
singleplex or multiplex reverse transcription and qRT-PCR
reaction. MiRNA expression was veriﬁed using individual
TaqMan-based qRT-PCR assays for let-7a and let-7c (Life
Technologies; TaqMan Assay ID #000377, #000379, respectively). Reverse transcription reactions were performed on 9.16
μL of eluted total RNA with the TaqMan MicroRNA Reverse
Transcription Kit and miRNA-speciﬁc stem-loop primers (Life
Technologies) on a Applied Biosystems Veriti 96-well thermal
cycler (Life Technologies) as previously described.26 qRTPCR reactions were prepared in triplicate; each reaction
contains 1 μL of TaqMan real-time miRNA assay, 4.5 μL of
reverse-transcribed RNA, 10 μL of TaqMan 2X Universal PCR
Master Mix, No AmpErase UNG, and 4.5 μL of nuclease-free
water. Real-time PCR reactions were run using an Applied
Biosystems StepOnePlus Real-Time PCR System (Life
Technologies) under the following conditions: 95 °C for 10
min, 40 cycles of 95 °C for 15 s, and 60 °C for 1 min. MiRNA
expression was normalized to the endogenous serum reference
gene miR-425-5p (Life Technologies; TaqMan Assay
ID#001516) to obtain ΔCt values (Ct mirCt miR-425-5p)
as previously described.27 Average fold diﬀerences between
noncancer (NC), low-risk (LR), and high-risk (HR) cancer
serum relative to QC serum (representing pooled 360
noncancer patients) miRNA expression values were obtained
using the ΔΔCt method.

(MPTES, 94%) were procured from Thermo Scientiﬁc and
used as received. Synthesized single-stranded DNA (ssDNAs)
and miRNA oligonucleotides (hsa-let-7a, hsa-let-7c, hsa-miR141-3p, hsa-miR-21-5p, hsa-miR-200b-3p) were procured from
Integrated DNA Technologies.
2.2. Spectroscopy and Microscopy Characterizations.
Absorption and extinction spectra in the range of 400−1000
nm were collected with a Spectra. Max M5 microplate reader
from Molecular Devices, LLC. Extinction spectra of AuNPs, in
the solution phase, were measured to determine the LSPR
peak position (λLSPR). For the calibration study, all transmission spectra were obtained in phosphate-buﬀered saline
(PBS) for all TOF using a Superk Compact supercontinuum
lasers in the range of 450−2400 nm and a compact CzernyTurner CCD spectrometer (CCS200, Thorlabs Inc.) as the
laser source and detector, respectively, at room temperature.
The resulting spectra were displayed on the computer for
visualization.
2.3. Fabrication and Functionalized TOF. The tapered
ﬁber was fabricated using a tapering rig system (Aerotech
PR0115SL system) to form the TOF structure. Brieﬂy, the
middle section of a 1 m length single-mode ﬁber (SMF) was
stripped of the polymer buﬀer coating material and cleaned
with acetone prior to stretching through ﬂame brushing
technique and placed on the tapering rig system.25 A butane
ﬂame was used to heat the ﬁber while pulling the ﬁber in the
x−y direction and oscillating the butane ﬂame in the zdirection (5,10,15) for 30 s to achieve a constant waist
diameter. The 3 cm region of the fabricated TOF was
transitioned from a diameter of 125 μm to a taper waist
diameter of ∼5 μm. The fabricated TOF was then carefully
removed from the stage and mounted on a Teﬂon substrate
that consisted of a 48 mm × 6 mm × 2 mm (l × w × d) cell to
contain the analyte within the tapered region for surface
functionalization and miRNA proﬁling (Scheme 1A). The
substrate surface was sealed with poly(dimethylsiloxane)
(PDMS) while exposing inlets and outlets.
2.4. Functionalization of TOF. The TOF was separately
functionalized through two steps: MPTMS derivatization and
gold triangular nanoprism (AuTNP) lamination. In the former
step, TOFs were cleaned in a mixture of HCl/MeOH (1:1)
followed by copious washing in DI water and dried in air for 3
h. The dried TOFs were immersed in 15% MPTMS−ethanol
solution for 30 min followed by an ethanol rinse to remove
unbound MPTMS from the TOF surface. In the later step, we
synthesized AuTNPs by following previously published
methods.16. Brieﬂy, 10 mg of Et3PAu(I)Cl was dissolved in
40 mL of CH3CN and stirred at medium speed for 5−10 min
at room temperature. Then, 0.038 mL of TEA was added to
the reaction mixture and heated gradually to 40 °C for 20 min.
Then, 0.6 mL of PMHS was added to the solution and stirred
for 3 h. The resulting solution was centrifuged at 4500 rpm for
40 min to remove the unreacted PMHS, and the obtained
precipitation was redissolved in ultrapure water and analyzed
using UV visible spectroscopy. The derivatized TOF was
placed in 800 μL of AuTNPs for 1 h to laminate the TOF with
Au nanostructures.
2.5. Biosensor Detection of miRNAs. The AuTNPlaminated TOFs were separately incubated in the respective 5
μM complementary ssDNA probe solution (ssDNA-HS(CH2)n‑X/SH (where X is the complementary base pairs for
the target miRNA)) and 0.1 M tris(2-carboxyethyl) phosphine
(TCEP) solution for 1 h to reduce disulﬁde to thiol. A 1 mM
2413
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3. RESULTS AND DISCUSSION
The potential clinical utility of miRNAs as biomarkers for
cancers can provide a direct link to cancer diagnosis and
prognosis as miRNAs are expressed in PCa cells and released
into the surrounding biological ﬂuids during disease progression. In biological ﬂuids (e.g., serum), endogenous
components such as proteins, cells, nucleotides, and pathogens
have a propensity to strongly bind to the sensor’s surface and
thereby inﬂuence the performance accuracy (false-positive and
false-negative responses) of diagnostic devices. In the present
study, we determined if our improved plasmonic-based
biosensor could detect miRNA levels with high sensitivity in
a complex human ﬂuid such as serum collected from the whole
blood of noncancer and PCa patients. We previously identiﬁed
a panel of PCa miRNA biomarkers (let-7a, let-7c, miR-141,
miR-21, miR-200b) for the development of our nanoplsmonic
TOF biosensor for PCa detection. Our previous studies
revealed successful detection of miRNAs when diluted in a
standard buﬀered solution using the functionalized AuTNPsTOF-immobilized ssDNA/PEG-SH for hybridization with the
synthetic target miRNA.18 To prevent biofouling of the sensor
surface, PEG4-SH was grafted on AuTNPs as a spacer molecule
to minimize nonspeciﬁc binding. In addition to its high water
solubility and low toxicity, the combination of steric hindrance
eﬀects, chain length, grafting density, and chain conformation
of PEG makes it an ideal antifouling molecule in biological
environments. PEG grafting has been widely implemented as
an antifouling polymer.28
Using the experimental setup described in Scheme 1, we
measured miR-21 in diluted human QC serum (40% in PBS),
representing a serum pool collected from 360 noncancer
individuals. The Δλpeak was calculated as a function of time
during target miR-21 hybridization with a ssDNA21-C3SH:PEG-SH-functionalized AuTNPs-TOF plasmonic biosensor (Figure 1). An average Δλpeak red shift of 14.0 ± 0.8 nm

delivered to the biosensor for miRNA detection. The shift in
transmission wavelength (Δλ) of the ssDNA/PEG thiolfabricated AuTNPs laminated TOF plasmonic sensor upon
hybridization of target miRNA in human serum in the range of
100 nM−1 fM was obtained. The sensor’s sensitivity and limit
of detection (LOD) along with the regression coeﬃcient for
each miRNA detected were calculated (Table 1).25 The LODs
Table 1. AuTNP TOF Biosensor Regression
Characteristics25
microRNA

sensitivity (nm/nM)

R2

LOD (aM)

let-7a
miR-141
let-7c
miR-21
miR-200b

1.0141
0.9026
0.9171
0.9084
0.9714

0.9761
0.9903
0.9817
0.9819
0.9827

394
252
242
580
179

obtained for miR-200b, let-7c, miR-141, and let-7a were 179,
242, 252, and 394 aM, respectively, with a sensitivity ranging
from 0.9714 to 1.0141 nm/nM. A slightly higher LOD of 580
was obtained for miR-21. The Δλpeak was observed to be
correlated with miRNA concentration levels with a regression
coeﬃcient ranging from 0.9761 to 0.9903. These results
exhibited improved LOD and sensitivity over our previously
fabricated TOF plasmonic biosensor.25
To minimize the possibility of false-positive and falsenegative responses, the selectivity characterization was
performed using the complementary ssDNA probe to target
miR-21 in 40% human serum. The spectrum obtained for the
plasmonic sensor is shown in Figure 2 (green curve) with a
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Figure 2. Transmission spectra demonstrating the selectivity of the
fabricated TOF plasmonic biosensor. Green curveAuTNP TOF
plasmonic biosensor (776.8 nm), black curveafter immobilization
of ssDNA21-C3-S-H: PEG4-SH (799 nm), red curveafter
incubation in a solution mixture of microRNAs let-7a, let-7c, miR200b, miR-141, and miR-21 (100 nM equimolar, 799.2 nm), and blue
curveafter miR-21 hybridization (824.5 nm) in human serum.
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Figure 1. Change in transmission wavelength as a function of time
during target miR-21 hybridization with ssDNA21-C3-SH:PEG-SHfunctionalized AuTNPs-TOF with error bars (triplicates).

λ peak of 776.8 nm. Upon functionalization with the
complementary ssDNA to target miR-21, the transmission
peak red-shifted by 22.2−799 nm (black curve). The exposure
of the ssDNA-functionalized biosensor to a solution mixture of
100 nM equimolar of miRNAs let-7a, let-7c, miR-200b, and
miR-141 resulted in no signiﬁcant shift in the Δλ peak (red
curve overlapping black curve). Subsequently, the biosensor
was incubated in 100 nM miR-21 in 40% human serum, which
resulted in a 25.3 nm red shift in the λpeak to 824.5 nm (blue
curve). These results indicated high selectivity of the biosensor
toward the target miRNA. We then validated the selective

was observed after 4 h of hybridization followed by a plateau in
the Δλpeak signal (Figure 1). The 4 h response time for
ssDNA-miRNA hybridization enables the potential application
of the TOF plasmonic biosensor in POC diagnosis. We then
evaluated the linear response characteristics for a panel of PCa
tumor suppressor and oncogenic miRNAs (let-7a, let-7c, miR141, miR-21, miR-200b) using 40% human serum spiked with
a predeﬁned volume of 1 μM target miRNA to achieve a 1
fM−100 nM miRNA dilution curve in human serum. Eight
hundred microliters of the miRNA-spiked serum solution was
2414
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----------------------binding of the target miRNA to the complementary ssDNA
receptor in noncancer and cancer patient serums using the
TOF plasmonic biosensor and qRT-PCR.
3.1. Detection of microRNAs in PCa Patient Samples.
The performance of the fabricated plasmonic biosensor was
evaluated using seven human serum samples obtained from
patients diagnosed with high-risk (HR), low-risk (LR) PCa
and compared to noncancer (NC) patients. Two samples were
obtained for each clinical PCa category, and three samples
were obtained for noncancer controls. We tested if the
plasmonic biosensor could be used to measure cancerassociated miRNAs in patient serums and diﬀerentiate between
the clinical groups for PCa (Figure 3A−E). The levels of tumor
suppressors miR-141, miR-200b, let-7a, and let-7c detected by
the plasmonic biosensor were in the range of pM to fM in
noncancer control serums and at lower concentrations in highrisk and low-risk patient samples. Figure 3A shows 110−290
fM, 18−28 fM, and 4−5 fM miR-141 in noncancer, low-risk,
and high-risk patients, respectively. Likewise, low levels of miR141 have been reported in the blood of PCa patients and
function to block tumor growth and metastasis by targeting a
cohort of pro-metastasis genes.29,30
Reduction of let-7 family members such as let-7a and let-7c
are commonly observed in PCa patients and in castrationresistant PCa (CRPC) cells.31 They have been shown to
inhibit PCa cell proliferation and clonal expansion in vitro and
in vivo28 by targeting cell cycle progression genes such as E2F2
and CCND2. The biosensor results revealed that let-7a is
overall less abundant than let-7c and is expressed at the fM
level, whereas let-7c is expressed at the pM level in human
serum (Figure 3B,C). As expected, let-7 levels were reduced in
PCa cancer patients. For let-7a, noncancer serum levels were
58−90 fM, whereas low-risk and high-risk PCa serum levels
dropped to 2−5 and 5−20 fM, respectively. Similar trends
were noted for let-7c, and this miRNA was expressed at 0.8−
1.2 pM in noncancer patient serum compared to 0.2−0.5 pM
in low-risk and 0.4−0.5 pM in high-risk PCa serum.
In addition, miR-200b has also been identiﬁed as a PCa
tumor suppressor miRNA that directly targets the androgen
receptor and its expression is linked to decreased tumorigenicity and metastatic capacity of PCa cells.32 Figure 3D
shows miR-200b was expressed at 4−7, 0.1, and 0.1 pM in
noncancer, low-risk, and high-risk patients, respectively. Oneway ANOVA analysis showed that these tumor suppressor
miRNAs (miR-141, miR-200b, let-7a, and let-7c) shown in
Figure 3 oﬀset panels could distinguish between the patient
groups with high detection selectivity and a p-value <0.0001
for high-risk vs low-risk PCa patients. Figure 3E indicates that
miR-21 expression was elevated in low-risk (4−5 pM) and
high-risk (7−8 pM) patients compared to noncancer patients
(0.3 pM). These ﬁndings are consistent with the oncogenic
role for miR-21 to target and inhibit tumor suppressor gene
PTEN expression and promote PCa cell proliferation and
invasion.33−36 miR-21 also showed a p-value <0.0001 for
identiﬁcation of noncancer control and high-risk vs low-risk
patient groups.
Our data therefore indicated that the AuTNP-laminated
TOF-based biosensor using serum expression proﬁles of these
tumor suppressors and oncogenic-associated miRNAs could
diﬀerentiate disease status. Indeed, the receiver operating
characteristic (ROC) analysis shown in Figure 4 showed that
the TOF plasmonic biosensor discriminated between the
noncancer control group and the PCa groups (low-risk or
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Table 2. Relative miRNA Expression Using qRT-PCR
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Figure 4. Receiver operating characteristics (ROC) for NC vs disease
patient samples.

high-risk patients) with an area under the curve (AUC) of 1.0.
This agreed with ﬁndings by Mitchell et al., where circulating
miRNA-141 could discriminate PCa patients from noncancer
patients.37
3.2. Relative Quantiﬁcation of Serum miRNA Expression by qRT-PCR. We went on to examine two of the
tumor suppressive miRNAs via conventional qRT-PCR
methods for relative quantiﬁcation analysis to compare
miRNA expression proﬁles in noncancer, low-risk, and highrisk PCa patients from the same serum specimens used for the
AuTNP-laminated TOF-based biosensor studies. Figure 5
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4. CONCLUSIONS
The AuTNP-laminated TOF plasmonic biosensor was
successfully demonstrated using chemically synthesized
plasmonic AuTNPs coupled with TOF to be a highly selective
and speciﬁc miRNA assay in noncancer and PCa patient
serums. A panel of miRNAs was quantiﬁed in human serum
with a LOD in the aM range and a good miRNA hybridization
response time of 4 h. As a proof-of-concept, the panel of
miRNAs was assayed directly from the unmodiﬁed serum of
seven patients with PCa. The biosensor demonstrated high
speciﬁcity (p-value of <0.0001, AUC = 1.0) toward detection
of the panel of miRNAs for early-stage diagnosis of PCa. The
high speciﬁcity of fabricated biosensors may signiﬁcantly
advance the biosensing ﬁeld by providing a POC tool to
perform early-stage diagnosis and prognosis of diseases using
miRNA or other biomarkers. The ﬂexibility of this
experimental setup has the potential to enable a wide range
of POC applications for early disease diagnosis using miRNAbased biosensors as a promising noninvasive tool to diagnose
PCa, where higher values on oncogenic and lower values of
tumor suppressor miRNAs are signiﬁcantly correlating with the
presence of high-risk and metastatic disease. Although the
panel of miRNAs was assayed using the fabricated biosensor to
demonstrate proof-of-concept early-stage PCa diagnosis
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7c for noncancer (NC), low-risk (LR), and high-risk (HR)
patient groups, respectively. Our qRT-PCR analysis showed
higher serum let-7a expression in noncancer individuals versus
low-risk and high-risk PCa patients, which correlated with the
results obtained using the TOF plasmonic biosensor. let-7c
expression followed similar trends by qRT-PCR when
comparing noncancer and low-risk patient groups; however,
the large standard deviation for the high-risk group made this
data point diﬃcult to interpret. Larger clinical cohorts of
human serum comparing miRNA expression levels using our
biosensor and qRT-PCR are needed for further validation as
well as the use of quantitative qRT-PCR rather than relative
qRT-PCR methodologies.
Our study suggests that the use of miRNAs as biomarkers
will provide tremendous opportunities for the development of
point-of-care (POC) diagnostic tools to advance human health
outcomes. To our knowledge, this study is the ﬁrst to
implement a TOF plasmonic biosensor for the detection of
PCa miRNAs biomarkers. Furthermore, this work demonstrated that the TOF ssDNA-modiﬁed biosensor oﬀers a highly
selective receptor for the target miRNA detection for the early
diagnosis of PCa directly from the patient’s serum. Despite the
limitation of a small patient cohort for this study, future studies
building upon this work are envisioned to enable highthroughput miRNA assays on unmodiﬁed human ﬂuids
through the advancement of a sensor platform to a fully
integrated microﬂuidic chip with multichannels for ultrasensitive quantiﬁcation of miRNAs. Therefore, fabricated TOF
plasmonic biosensors may have potential use for noninvasive
miRNA diagnostic purposes in a large range of human
disorders.
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Figure 5. qRT-PCR of PCa-associated miRNAs. (A) let-7a and (B)
let-7c in noncancer, low-risk, and high-risk patients. Oﬀset panels
represent ANOVA results for NC vs LR vs HR samples.

depicts the serum values obtained for let-7a and let-7c in the
seven patients analyzed by TaqMan-based qRT-PCR. MiRNA
expression for each individual patient serum was measured in
triplicate relative to the miRNA expression proﬁled in the QC
serum sample (representing pooled 360 noncancer patients),
and the averaged fold diﬀerences were obtained using the
comparative cycle threshold (ΔΔCt) method. Serum sample
expression was normalized to the endogenous miRNA
reference gene miR-425-5p.20 Table 2 provides the mean
serum values by qRT-PCR of tumor suppressors let-7a and let2416
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toward improved health outcomes and patient survival rates, a
larger cohort of PCa patients will need to be analyzed using
this biosensor platform for biomarker validation.
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